Computational investigation of the HIV-1 Rev multimerization using molecular dynamics simulations and binding free energy calculations

Proteins: Structure, Function and Bioinformatics

Volumn 80, Issue 6, 2012, Pages 1633-1646

  Venken, Tom ^a   Daelemans, Dirk ^b   De Maeyer, Marc ^a   Voet, Arnout ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

HIV 1 replication; MM GBSA; MM PBSA; Molecular dynamics; Nuclear export; Rev

Indexed keywords

AMINO ACID; ARGININE; REV PROTEIN;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CALCULATION; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; ENERGY; ENTROPY; FORCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MULTIMERIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; THERMODYNAMICS;

ARGININE; HIV-1; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860605119     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24057     Document Type: Article

References (55)

1. Pollard VW, Malim MH (1998) The HIV-1 Rev protein. Annu Rev Microbiol 52: 491-532.
2. Groom HC, Anderson EC, Lever AM (2009) Rev: beyond nuclear export. J Gen Virol 90: 1303-1318.
3. Daly TJ, Cook KS, Gray GS, Maione TE, Rusche JR (1989) Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 342: 816-819.
4. Daly TJ, Doten RC, Rennert P, Auer M, Jaksche H, Donner A, Fisk G, Rusche JR (1993) Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive element. Biochemistry 32: 10497-10505.
5. Mann DA, Mikaelian I, Zemmel RW, Green SM, Lowe AD, Kimura T, Singh M, Butler PJ, Gait MJ, Karn J (1994) A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol 241: 193-207.
6. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, Nishida E (1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308-311.
7. Fang J, Kubota S, Yang B, Zhou N, Zhang H, Godbout R, Pomerantz RJ (2004) A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology 330: 471-480.
8. Yedavalli VS, Neuveut C, Chi YH, Kleiman L, Jeang KT (2004) Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119: 381-392.
9. Suhasini M, Reddy TR (2009) Cellular proteins and HIV-1 Rev function. Curr HIV Res 7: 91-100.
10. Malim MH, Cullen BR (1991) HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 65: 241-248.
11. Malim MH, Bohnlein S, Hauber J, Cullen BR (1989) Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function. Cell 58: 205-214.
12. Jain C, Belasco JG (2001) Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol Cell 7: 603-614.
13. Edgcomb SP, Aschrafi A, Kompfner E, Williamson JR, Gerace L, Hennig M (2008) Protein structure and oligomerization are important for the formation of export-competent HIV-1 Rev-RRE complexes. Protein Sci 17: 420-430.
14. Chapman RL, Stanley TB, Hazen R, Garvey EP (2002) Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening. Antiviral Res 54: 149-162.
15. Mills NL, Daugherty MD, Frankel AD, Guy RK (2006) An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction. J Am Chem Soc 128: 3496-3497.
16. Shuck-Lee D, Chen FF, Willard R, Raman S, Ptak R, Hammarskjold ML, Rekosh D (2008) Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 52: 3169-3179.
17. Wolff B, Sanglier JJ, Wang Y (1997) Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4: 139-147.
18. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme AM (2002) A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA 99: 14440-14445.
19. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D (2008) Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 16: 9487-9497.
20. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D (2010) An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem 285: 21768-21780.
21. Vercruysse T, Pawar S, De Borggraeve W, Pardon E, Pavlakis GN, Pannecouque C, Steyaert J, Balzarini J, Daelemans D (2011) Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer. RNA Biol 8: 316-324.
22. Daugherty MD, D'Orso I, Frankel AD (2008) A solution to limited genomic capacity: using adaptable binding surfaces to assemble the functional HIV Rev oligomer on RNA. Mol Cell 31: 824-834.
23. Daugherty MD, Booth DS, Jayaraman B, Cheng Y, Frankel AD (2010) HIV Rev response element (RRE) directs assembly of the Rev homooligomer into discrete asymmetric complexes. Proc Natl Acad Sci USA 107: 12481-12486.
24. Auer M, Gremlich HU, Seifert JM, Daly TJ, Parslow TG, Casari G, Gstach H (1994) Helix-loop-helix motif in HIV-1 Rev. Biochemistry 33: 2988-2996.
25. Pond SJ, Ridgeway WK, Robertson R, Wang J, Millar DP (2009) HIV-1 Rev protein assembles on viral RNA one molecule at a time. Proc Natl Acad Sci USA 106: 1404-1408.
26. Daelemans D, Costes SV, Cho EH, Erwin-Cohen RA, Lockett S, Pavlakis GN (2004) In vivo HIV-1 Rev multimerization in the nucleolus and cytoplasm identified by fluorescence resonance energy transfer. J Biol Chem 279: 50167-50175.
27. Pallesen J, Dong M, Besenbacher F, Kjems J (2009) Structure of the HIV-1 Rev response element alone and in complex with regulator of virion (Rev) studied by atomic force microscopy. FEBS J 276: 4223-4232.
28. Havlin RH, Blanco FJ, Tycko R (2007) Constraints on protein structure in HIV-1 Rev and Rev-RNA supramolecular assemblies from two-dimensional solid state nuclear magnetic resonance. Biochemistry 46: 3586-3593.
29. DiMattia MA, Watts NR, Stahl SJ, Rader C, Wingfield PT, Stuart DI, Steven AC, Grimes JM (2010) Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element. Proc Natl Acad Sci USA 107: 5810-5814.
30. Daugherty MD, Liu B, Frankel AD (2010) Structural basis for cooperative RNA binding and export complex assembly by HIV Rev. Nat Struct Mol Biol 17: 1337-1342.
31. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE, III (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
32. Onufriev A, Bashford D, Case DA (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55: 383-394.
33. Karplus M, Andricioaei I (2001) On the calculation of entropy from covariance matrices of the atomic fluctuations. J Chem Phys 115: 6289-6292.
34. Carlsson J, Aqvist J (2005) Absolute and relative entropies from computer simulation with applications to ligand binding. J Phys Chem B 109: 6448-6456.
35. Zhao Y, Li W, Zeng J, Liu G, Tang Y (2008) Insights into the interactions between HIV-1 integrase and human LEDGF/p75 by molecular dynamics simulation and free energy calculation. Proteins 72: 635-645.
36. Tintori C, Veljkovic N, Veljkovic V, Botta M (2010) Computational studies of the interaction between the HIV-1 integrase tetramer and the cofactor LEDGF/p75: insights from molecular dynamics simulations and the informational spectrum method. Proteins 78: 3396-3408.
37. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, Bardiot D, Van der Veken NJ, Van Remoortel B, Strelkov SV, De Maeyer M, Chaltin P, Debyser Z. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chemical Biology 2010; 6(6): 442-448.
38. Cavalluzzo C, Voet A, Christ F, Singh BK, Sharma A, Debyser Z, De Maeyer M, Van der Eycken E (2012) De novo design of small molecule inhibitors targeting the LEDGF/p75-HIV integrase interaction. RSC Adv 2: 974-984.
39. De Luca L, Barreca ML, Ferro S, Christ F, Iraci N, Gitto R, Monforte AM, Debyser Z, Chimirri A (2009) Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 4: 1311-1316.
40. Stites WE (1997) Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem Rev 97: 1233-1250.
41. Wang J, Morin P, Wang W, Kollman PA (2001) Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBOderivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 123: 5221-5230.
42. Huo S, Massova I, Kollman PA (2002) Computational alanine scanning of the 1:1 human growth hormone-receptor complex. J Comput Chem 23: 15-27.
43. Zhou Z, Madura JD (2004) Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS. Proteins 57: 493-503.
44. Yogurtcu ON, Erdemli SB, Nussinov R, Turkay M, Keskin O (2008) Restricted mobility of conserved residues in protein-protein interfaces in molecular simulations. Biophys J 94: 3475-3485.
45. Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theor Comput 4: 435-447.
46. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
47. Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126: 014101.
48. Parrinello M, Rahman A (1981) Polymorphic transitions in single-crystals-a new molecular-dynamics method. J Appl Phys 52: 7182-7190.
49. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C (2006) Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
50. Case DA, Cheatham TE, III, Darden T, Gohlke H, Luo R, Merz KM, Jr, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
51. Venken T, Krnavek D, Munch J, Kirchhoff F, Henklein P, De Maeyer M, Voet A (2011) An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor. Proteins 79: 3221-3235.
52. Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. JChem Inf Model 51: 69-82.
53. DeLano W (2002) The PyMOL molecular graphics system. San Carlos: DeLano Scientific.
54. Mustata G, Follis AV, Hammoudeh DI, Metallo SJ, Wang H, Prochownik EV, Lazo JS, Bahar I (2009) Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem 52: 1247-1250.
55. Mustata G, Li M, Zevola N, Bakan A, Zhang L, Epperly M, Greenberger JS, Yu J, Bahar I. Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. Curr Top Med Chem 2011; 11: 281-290.